In the Press COUR Pharmaceuticals Announces $30M Financing Led by Alpha Wave Ventures September 2022 Read More COUR Pharmaceuticals Appoints Brian C. Bock as Chief Financial Officer March 2022 Read More COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the Treatment of Primary Biliary Cholangitis January 2022 Read More CBRE Arranges Expansion Lease for Cour Pharmaceuticals November 2021 Read More
COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the Treatment of Primary Biliary Cholangitis January 2022 Read More
